Results for tag: "Filgrastim Biosimilars"

Filgrastim is a biologic drug that stimulates the production of white blood cells and is commonly used to treat neutropenia, a condition characterized by low levels of neutrophils, often induced by chemotherapy treatment for cancer. The entry of filgrastim biosimilars into the oncology drugs market marks an important development for healthcare practitioners and patients alike, as these biosimilars offer a more cost-effective alternative to the original biologic while maintaining similar safety and efficacy profiles. Biosimilars are approved by regulatory agencies based on comprehensive data demonstrating their equivalence in terms of potency, safety, and purity. These agents are instrumental in supportive cancer care, allowing for better management of the side effects associated with chemotherapy. Increased adoption of filgrastim biosimilars can improve patient access to essential medications, particularly in markets with cost constraints and in healthcare settings where the economic burden is a major factor in treatment decisions. Companies currently producing filgrastim biosimilars include Sandoz with its product Zarxio, the first biosimilar approved in the United States, and Teva Pharmaceuticals with Granix. Other players in the market encompass Pfizer, which offers Nivestym, as well as Amgen, which introduced a filgrastim-sndz biosimilar branded as Neupogen. Additionally, Mylan and Biocon jointly developed Fulphila, which also constitutes a part of the competitive landscape of the filgrastim biosimilars market. Show Less Read more